Ryan Deschner
Stock Analyst at Raymond James
(4.74)
# 142
Out of 5,042 analysts
18
Total ratings
70.59%
Success rate
43.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVRD Tvardi Therapeutics | Downgrades: Market Perform | n/a | $4.65 | - | 2 | Oct 14, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $33 → $41 | $24.36 | +68.31% | 4 | Aug 13, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $11.66 | +131.56% | 3 | Aug 8, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $54 | $79.84 | -32.36% | 1 | Aug 6, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $6.06 | +98.02% | 2 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $52 → $50 | $21.47 | +132.88% | 2 | Aug 1, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $38.08 | +220.38% | 1 | Jul 24, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $8.96 | +212.50% | 3 | Jan 14, 2025 |
Tvardi Therapeutics
Oct 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $4.65
Upside: -
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33 → $41
Current: $24.36
Upside: +68.31%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $11.66
Upside: +131.56%
Palvella Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $54
Current: $79.84
Upside: -32.36%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $6.06
Upside: +98.02%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $52 → $50
Current: $21.47
Upside: +132.88%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $38.08
Upside: +220.38%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $8.96
Upside: +212.50%